Aktis Oncology, Inc. AKTS
19.43
(0.20)
(1.02%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 0.0×
Follow AKTS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | — | — | (34.45%) | |
| — | 0.00% | 0.00% | (27.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (14.86%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(72.96) | 0.00 | (2.82) | (2.52) | |
Free Cash Flow |
(58.90) | (98.90) | (136.90) | (139.37) | |
Capital Expenditures |
(10.00) | (15.87) | (14.87) | (14.23) | |
Piotroski F-Score |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | (20.05%) | (11.68%) | (12.49%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 826.24% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 212.89% | |
Share Based Compensation of Revenue |
— | — | — | 93.15% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 1.66 | |
Depreciation/Fixed assets |
0.00 | (0.48) | (0.28) | (0.19) | |
Capex/Depreciation |
1.50 | 2.29 | 3.45 | 4.61 | |
Revenue per Share |
0.00 | — | 0.00 | 0.17 | |
Operating CF per Share |
(60.58) | 0.00 | (2.51) | (2.26) | |
Capex per Share |
(12.38) | 0.00 | (0.31) | (0.26) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.47 | |
Net Profit Margin |
— | — | — | (781.95%) |
Columns are period end dates